Exploiting invariant NKT cells to promote T-cell responses to cancer vaccines

Invariant natural killer T (iNKT) cells have the capacity to amplify adaptive immune responses by licensing antigen-presenting cells. A simple vaccine consisting of whole tumor cells pulsed with an iNKT-cell agonist efficiently delivers antigens plus adjuvants to endogenous dendritic cells and has p...

Descripción completa

Detalles Bibliográficos
Autores principales: Hunn, Martin K., Hermans, Ian F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654595/
https://www.ncbi.nlm.nih.gov/pubmed/23734325
http://dx.doi.org/10.4161/onci.23789
Descripción
Sumario:Invariant natural killer T (iNKT) cells have the capacity to amplify adaptive immune responses by licensing antigen-presenting cells. A simple vaccine consisting of whole tumor cells pulsed with an iNKT-cell agonist efficiently delivers antigens plus adjuvants to endogenous dendritic cells and has potential for clinical applications.

Ejemplares similares